AZD0530 is a dually active inhibitor of c-Src and Bcr-ABL, on bone resorption. AZD0530 inhibited tumor growth in a manner independent of dose and inhibited phosphorylation of focal adhesion kinase (FAK) and paxillin in a dose-dependent manner in a Calu-6 Xenograft model.